Newron Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Newron Pharmaceuticals Il CEO è Stefan Weber, nominato in Jun2012, e ha un mandato di 12.42 anni. la retribuzione annua totale è € 510.00K, composta da 93.1% di stipendio e 6.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.1% delle azioni della società, per un valore di CHF 147.33K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 12.4 anni e 12.8 anni.

Informazioni chiave

Stefan Weber

Amministratore delegato

€510.0k

Compenso totale

Percentuale dello stipendio del CEO	93.1%
Mandato del CEO	12.4yrs
Proprietà del CEO	0.1%
Durata media del management	12.4yrs
Durata media del Consiglio di amministrazione	12.8yrs

Aggiornamenti recenti sulla gestione

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11

Recent updates

Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues

Sep 03

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Nov 06

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Apr 06

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Apr 01

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

Feb 25

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Stefan Weber rispetto agli utili di Newron Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-€19m
Mar 31 2024	n/a	n/a	-€18m
Dec 31 2023	€510k	€475k	-€16m
Sep 30 2023	n/a	n/a	-€16m
Jun 30 2023	n/a	n/a	-€16m
Mar 31 2023	n/a	n/a	-€17m
Dec 31 2022	€498k	€429k	-€17m
Sep 30 2022	n/a	n/a	-€16m
Jun 30 2022	n/a	n/a	-€14m
Mar 31 2022	n/a	n/a	-€15m
Dec 31 2021	€510k	€414k	-€15m
Sep 30 2021	n/a	n/a	-€17m
Jun 30 2021	n/a	n/a	-€20m
Mar 31 2021	n/a	n/a	-€20m
Dec 31 2020	€582k	€403k	-€21m
Sep 30 2020	n/a	n/a	-€19m
Jun 30 2020	n/a	n/a	-€17m
Mar 31 2020	n/a	n/a	-€18m
Dec 31 2019	€691k	€440k	-€20m
Sep 30 2019	n/a	n/a	-€21m
Jun 30 2019	n/a	n/a	-€21m
Mar 31 2019	n/a	n/a	-€18m
Dec 31 2018	€647k	€430k	-€15m
Sep 30 2018	n/a	n/a	-€15m
Jun 30 2018	n/a	n/a	-€14m
Mar 31 2018	n/a	n/a	-€10m
Dec 31 2017	€563k	€418k	-€5m

Compensazione vs Mercato: La retribuzione totale di Stefan ($USD 536.39K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Swiss ($USD 807.30K ).

Compensazione vs guadagni: La retribuzione di Stefan è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Stefan Weber (59 yo)

12.4yrs

Mandato

€510,000

Compensazione

Mr. Stefan Weber serves as the Chief Financial Officer and Finances and Administration Director at Duktus S.A. Mr. Weber has been the Chief Executive Officer of Newron Pharmaceuticals SpA since June 1, 201...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Stefan Weber	CEO & Executive Director	12.4yrs	€510.00k	0.10% CHF 147.3k
Roberto Galli	Chief Financial Officer	12.4yrs	Nessun dato	0.013% CHF 18.1k
Filippo Moriggia	Vice President of Operations	2.3yrs	Nessun dato	Nessun dato
Ravi Anand	Chief Medical Officer	19.5yrs	€1.12m	0.22% CHF 303.2k
Laura Faravelli	Vice President of Business Development	1.3yrs	Nessun dato	Nessun dato

12.4yrs

Durata media

Gestione esperta: Il team dirigenziale di NWRN è esperto e expertise (durata media dell'incarico 12.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Stefan Weber	CEO & Executive Director	12.8yrs	€510.00k	0.10% CHF 147.3k
Patrick Langlois	Independent Non-Executive Director	16.3yrs	€78.00k	0.062% CHF 86.9k
Ulrich Köstlin	Independent Non-Executive Chairman	11.6yrs	€106.00k	0.21% CHF 291.4k
Luca Benatti	Non-Executive & Independent Director	10.7yrs	€68.00k	Nessun dato
William Langston	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Ze' Seltzer	Member of Scientific & Clinical Advisory Board	no data	Nessun dato	Nessun dato
Fabrizio Stocchi	Member of Scientific and Clinical Advisory Board	no data	Nessun dato	Nessun dato
Emilio Perucca	Member of Scientific & Clinical Advisory Board	no data	Nessun dato	Nessun dato
Paolo Marchettini	Member of Scientific & Clinical Advisory Board	no data	Nessun dato	Nessun dato
Marco Onofrj	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Abraham Lieberman	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Richard Murphy	Chairman of the Board of Statutory Auditors	22.8yrs	€13.00k	Nessun dato

12.8yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di NWRN è composto da personale esperto e esperto (durata media dell'incarico 12.8 anni).

Newron Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 18, 2023

Insufficient new directors

Insufficient new directors

Recent updates

First half 2024 earnings released: €0.52 loss per share (vs €0.39 loss in 1H 2023)

New minor risk - Financial position

Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues

Newron Pharmaceuticals S.P.A Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

Forecast breakeven date pushed back to 2026

Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Consensus revenue estimates fall by 19%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Forecast breakeven date pushed back to 2025

Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia (TRS)

Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide

Newron Pharmaceuticals S.p.A. to Report Fiscal Year 2023 Results on Mar 19, 2024

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2023

Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor

New minor risk - Market cap size

Forecast breakeven date moved forward to 2023

Full year 2022 earnings released: €0.98 loss per share (vs €0.83 loss in FY 2021)

Newron Reports Striking One-Year Interim Efficacy Results from Its Phase Ii Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Announces Striking Six-Month Interim Results from Its Exploratory Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 18, 2023

Insufficient new directors

First half 2022 earnings released: €0.48 loss per share (vs €0.51 loss in 1H 2021)

Newron Pharmaceuticals S.P.A. Presents Encouraging Interim Results for Evenamide in Patients with Treatment-Resistant Schizophrenia (Trs) At the 33Rd Cinp Hybrid World Congress of Neuropsychopharmacology

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

First half 2021 earnings released: €0.51 loss per share (vs €0.59 loss in 1H 2020)

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA Filings for Xadago® (safinamide) in the USA

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2020 earnings released: €1.18 loss per share (vs €1.13 loss in FY 2019)

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 13, 2021

Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson’s Disease Patients

New 90-day high: CHF2.99

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

New 90-day high: CHF2.95

Newron Pharmaceuticals Completes Enrollment of Explanatory Safety and Efficacy Study with Evenamide in Schizophrenia Patients

New 90-day high: CHF2.25

New 90-day high: CHF2.11

Analysts lower EPS estimates to -€1.17

First half earnings released

New 90-day low - CHF1.55

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media